Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin-Reference-Cited by-同舟云学术

Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin

Published:2014-07-11 Issue:8 Volume:37 Page:1102-1107
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head Neck

Author:

Colevas A. Dimitrios¹,Lira Ruth R.¹,Colevas Electra A.¹,Lavori Philip W.²,Chan Cato³,Shultz David B.³,Chang Kay W.⁴

Affiliation:

1. Department of Medicine (Oncology), Stanford Cancer Institute; Stanford University; Stanford California

2. Department of Health Research and Policy - Biostatistics; Stanford University; Stanford California

3. Department of Radiation Oncology; Stanford University; Stanford California

4. Department of Otolaryngology/Head and Neck Surgery; Stanford University; Stanford California

Publisher

Wiley

Subject

Otorhinolaryngology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hed.23714/fullpdf

Reference19 articles.

1. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors;Brydøy;J Natl Cancer Inst,2009

2. Neurotoxicity secondary to antineoplastic drugs;Tuxen;Cancer Treat Rev,1994

3. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer;Bokemeyer;Br J Cancer,1998

4. Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients;Aguilar-Markulis;J Surg Oncol,1981

5. Practical grading system for evaluating cisplatin ototoxicity in children;Chang;J Clin Oncol,2010

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hear and Now: Ongoing Clinical Trials to Prevent Drug-Induced Hearing Loss;Annual Review of Pharmacology and Toxicology;2024-01-23

2. Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?;Cancer Treatment Reviews;2023-09

3. Sphingosine 1-Phosphate Receptor 2 Induces Otoprotective Responses to Cisplatin Treatment;Cancers;2020-01-15

4. Activation of sphingosine 1-phosphate receptor 2 attenuates chemotherapy-induced neuropathy;Journal of Biological Chemistry;2020-01

5. Activation of sphingosine 1-phosphate receptor 2 attenuates chemotherapy-induced neuropathy;Journal of Biological Chemistry;2019-12-27